IL1B and uveitis: RC-3095, a selective GRPR antagonist, has been shown to have anti-inflammatory properties in murine models of arthritis, gastritis, uveitis, and sepsis by attenuating the release of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-1-beta (IL-1β) and the activation and migration of mononuclear cells to sites of inflammation [15].